New agents and perspectives in the pharmacological treatment of major depressive disorder.
Antidepressants
Ketamine
Major depressive disorder
Pharmacology
Treatment
Journal
Progress in neuro-psychopharmacology & biological psychiatry
ISSN: 1878-4216
Titre abrégé: Prog Neuropsychopharmacol Biol Psychiatry
Pays: England
ID NLM: 8211617
Informations de publication
Date de publication:
02 03 2021
02 03 2021
Historique:
received:
17
08
2020
revised:
19
10
2020
accepted:
27
10
2020
pubmed:
8
11
2020
medline:
1
1
2022
entrez:
7
11
2020
Statut:
ppublish
Résumé
Despite the important advances in the understanding of the pathophysiology of MDD, a large proportion of depressed patients do not respond well to currently available pharmacological agents. The present review focuses on new targets and future directions in the pharmacological treatment of MDD. Novel agents and their efficacy in the treatment of depression are discussed, with a focus on the respectively target pathophysiological pathways and the level of available evidence. Although it is expected that classic antidepressants will remain the cornerstone of MDD treatment, at least for the near future, a large number of novel compounds is currently under investigation as for their efficacy in the treatment of MDD, many of which with promising results.
Identifiants
pubmed: 33159975
pii: S0278-5846(20)30473-5
doi: 10.1016/j.pnpbp.2020.110157
pmc: PMC7750246
mid: NIHMS1646064
pii:
doi:
Substances chimiques
Antidepressive Agents
0
Cholinergic Agents
0
GABA Agents
0
Hallucinogens
0
Opiate Alkaloids
0
Glutamic Acid
3KX376GY7L
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
110157Subventions
Organisme : NIMH NIH HHS
ID : R21 MH117636
Pays : United States
Informations de copyright
Copyright © 2020. Published by Elsevier Inc.
Références
Neurobiol Dis. 2010 May;38(2):237-45
pubmed: 20109548
Am J Psychiatry. 1965 Nov;122(5):509-22
pubmed: 5319766
World Psychiatry. 2019 Oct;18(3):308-324
pubmed: 31496103
Neuropsychopharmacology. 2019 Nov;44(12):2112-2118
pubmed: 31421635
J Psychopharmacol. 2016 Dec;30(12):1181-1197
pubmed: 27909165
CNS Spectr. 2019 Aug;24(S1):25-37
pubmed: 31248466
J Clin Psychiatry. 2012 Nov;73(11):1403-11
pubmed: 23146246
Exp Ther Med. 2018 Jun;15(6):5100-5106
pubmed: 29805536
J Clin Psychiatry. 2017 Jun;78(6):e656-e667
pubmed: 28682528
Biol Psychiatry. 2018 Nov 15;84(10):751-761
pubmed: 28886759
Psychiatry Res. 2020 Feb;284:112749
pubmed: 31931272
Int J Neuropsychopharmacol. 2019 Nov 1;22(11):735-745
pubmed: 31613314
Med Hypotheses. 2006;67(5):1185-8
pubmed: 16797865
J Clin Pharm Ther. 1999 Dec;24(6):461-9
pubmed: 10651979
Brain Res Bull. 2016 Sep;126(Pt 1):89-101
pubmed: 26976063
Nat Rev Dis Primers. 2016 Sep 15;2:16065
pubmed: 27629598
Curr Pharm Des. 2009;15(14):1563-86
pubmed: 19442174
J Psychiatr Res. 2010 Apr;44(6):339-46
pubmed: 19909979
Harv Rev Psychiatry. 2018 Nov/Dec;26(6):307-319
pubmed: 29465478
Neuroscience. 2010 Dec 29;171(4):1367-76
pubmed: 20933581
J Clin Psychopharmacol. 2017 Oct;37(5):505-511
pubmed: 28708736
JAMA Psychiatry. 2018 Feb 1;75(2):139-148
pubmed: 29282469
Expert Opin Pharmacother. 2016 Oct;17(14):1835-7
pubmed: 27477119
Front Psychiatry. 2014 Jan 24;5:2
pubmed: 24478730
Drugs. 2015 Nov;75(16):1915-23
pubmed: 26496736
Ment Health Clin. 2018 Jun 29;8(4):175-183
pubmed: 30155392
Control Clin Trials. 2004 Feb;25(1):119-42
pubmed: 15061154
Neuropsychiatr Dis Treat. 2018 Mar 13;14:741-747
pubmed: 29559781
J Affect Disord. 2018 Feb;227:219-225
pubmed: 29102836
Biol Psychiatry. 2002 Sep 1;52(5):386-92
pubmed: 12242054
Neurobiol Dis. 2017 Jan;97(Pt B):119-126
pubmed: 27425886
Curr Neuropharmacol. 2015;13(6):739-49
pubmed: 26630954
CNS Spectr. 2017 Oct;22(5):415-426
pubmed: 28181901
Pharmacol Ther. 2016 Aug;164:170-82
pubmed: 27139517
Neuropharmacology. 2016 Mar;102:72-9
pubmed: 26519901
Psychopharmacology (Berl). 2020 Jan;237(1):209-218
pubmed: 31712971
Neuropsychiatr Dis Treat. 2017 Mar 31;13:973-980
pubmed: 28408831
Cochrane Database Syst Rev. 2016 Oct 10;10:CD011286
pubmed: 27727432
J Affect Disord. 2019 Nov 1;258:11-24
pubmed: 31382100
PLoS One. 2015 Dec 30;10(12):e0145840
pubmed: 26716991
Brain Behav Immun. 2020 Jul;87:229-237
pubmed: 31794798
J Psychiatr Pract. 2015 Mar;21(2):140-9
pubmed: 25782764
Psychopharmacology (Berl). 2018 Feb;235(2):399-408
pubmed: 29119217
Harv Rev Psychiatry. 2020 Jan/Feb;28(1):40-59
pubmed: 31913981
Trends Pharmacol Sci. 2005 Dec;26(12):631-8
pubmed: 16246434
J Affect Disord. 2017 Aug 15;218:277-283
pubmed: 28478356
Brain Behav Immun. 2020 Jan;83:7-21
pubmed: 31550500
J Pharmacol Exp Ther. 2016 Feb;356(2):260-6
pubmed: 26628406
Lancet Psychiatry. 2016 Jul;3(7):619-27
pubmed: 27210031
Psychol Med. 2019 Mar;49(4):655-663
pubmed: 29903051
Front Psychiatry. 2020 Jan 21;10:943
pubmed: 32038315
Int J Mol Sci. 2013 Jun 13;14(6):12458-83
pubmed: 23765220
Expert Opin Pharmacother. 2019 Apr;20(6):647-656
pubmed: 30759026
Am J Psychiatry. 2015 Oct;172(10):950-66
pubmed: 26423481
J Psychopharmacol. 2018 Apr;32(4):377-384
pubmed: 29442609
Mol Psychiatry. 2011 Apr;16(4):383-406
pubmed: 21079608
N Engl J Med. 2019 Sep 5;381(10):903-911
pubmed: 31483961
J Clin Psychiatry. 2005 May;66(5):598-602
pubmed: 15889946
Endocrine. 2005 Jul;27(2):101-10
pubmed: 16217123
Expert Opin Investig Drugs. 2000 Aug;9(8):1871-5
pubmed: 11060783
Eur Neuropsychopharmacol. 2017 Jun;27(6):554-559
pubmed: 28479211
J Clin Psychopharmacol. 2011 Aug;31(4):436-40
pubmed: 21694614
PLoS Med. 2006 Nov;3(11):e442
pubmed: 17132052
Neuropsychopharmacology. 2016 Jun;41(7):1803-12
pubmed: 26585287
J Psychopharmacol. 2016 Dec;30(12):1165-1180
pubmed: 27909164
J Psychosoc Nurs Ment Health Serv. 2018 Oct 1;56(10):11-14
pubmed: 30278095
Expert Opin Pharmacother. 2020 Jan;21(1):9-20
pubmed: 31663783
Lancet. 2012 Mar 17;379(9820):1045-55
pubmed: 22189047
Lancet Psychiatry. 2016 Feb;3(2):117-27
pubmed: 26727041
Pharmacol Rev. 2018 Jul;70(3):475-504
pubmed: 29884653
Am J Psychiatry. 2006 Nov;163(11):1905-17
pubmed: 17074942
Braz J Psychiatry. 2015 Jan-Mar;37(1):13-20
pubmed: 25806551
Pharmacol Rev. 2012 Apr;64(2):238-58
pubmed: 22407616
Expert Opin Investig Drugs. 2019 Feb;28(2):113-119
pubmed: 30585524
Pharmacol Biochem Behav. 2020 Jan;188:172838
pubmed: 31837338
BMC Psychiatry. 2019 Oct 28;19(1):321
pubmed: 31660905
Arch Gen Psychiatry. 2006 Nov;63(11):1199-208
pubmed: 17088500
Pharmacotherapy. 2019 Nov;39(11):1105-1112
pubmed: 31514247
PLoS One. 2011;6(10):e26153
pubmed: 22039440
Expert Opin Emerg Drugs. 2010 Sep;15(3):453-66
pubmed: 20486861
Neuropsychopharmacology. 2016 Aug;41(9):2344-51
pubmed: 26979295
Drugs. 2017 Mar;77(4):381-401
pubmed: 28194724
Expert Opin Drug Discov. 2019 Jan;14(1):81-89
pubmed: 30457395
Transl Psychiatry. 2019 Aug 5;9(1):190
pubmed: 31383846
Psychopharmacology (Berl). 2016 Mar;233(6):1119-30
pubmed: 26728893
J Comp Neurol. 2006 Dec 20;499(6):897-910
pubmed: 17072839
BMJ. 2014 Mar 19;348:g1888
pubmed: 24647162
Psychiatry Res. 1995 Sep 29;58(2):99-105
pubmed: 8570773